Humanized anti-CCR2 antibodies and methods of use therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorsGregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
Life of this patent
Estimating the term…
Abstract
The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
Claims74
A humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 107 and a heavy chain variable region from an antibody having binding specificity for CCR2.
A composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain variable region from an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain variable region from an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2.
A composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2.
A composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2, and a physiologically acceptable vehicle.
A humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region comprising the amino acid sequence of SEQ ID NO:
- 107, and wherein said heavy chain comprises three complementarity determining regions derived from the heavy chain of murine monoclonal antibody 1D9 and a framework region derived from the heavy chain of human antibody 4B4′CL.
A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region comprising the amino acid sequence of SEQ ID NO:
- 107, and wherein said heavy chain comprises three complementarity determining regions derived from the heavy chain of murine monoclonal antibody 1D9 and a framework region derived from the heavy chain of human antibody 4B4′CL, and a physiologically acceptable vehicle.
A variable region comprising the amino acid sequence of SEQ ID NO:
- 107.
A humanized immunoglobulin light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:
- 107.
An antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 107 and a heavy chain variable region from an antibody having binding specificity for CCR2, wherein said antigen-binding fragment has binding specificity for CCR2.
A composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said humanized immunoglobulin comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain variable region from an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
A pharmaceutical composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said humanized immunoglobulin comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain variable region from an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
An antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2, said humanized immunoglobulin comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2, wherein said antigen-binding fragment has binding specificity for CCR2.
A composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said humanized immunoglobulin comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
A pharmaceutical composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said humanized immunoglobulin comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:107 and a heavy chain from an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
An antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2, said immunoglobulin comprising a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2, wherein said antigen-binding fragment has binding specificity for CCR2.
A composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said immunoglobulin comprises a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
A composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said immunoglobulin comprises a light chain and a heavy chain, said light chain comprising a variable region comprising the amino acid sequence of SEQ ID NO:107 and said heavy chain comprising three complementarity determining regions derived from the heavy chain of an antibody having binding specificity for CCR2, and wherein said antigen-binding fragment has binding specificity for CCR2.
An antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2, said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region comprising the amino acid sequence of SEQ ID NO:
- 107, and wherein said heavy chain comprises three complementarity determining regions derived from the heavy chain of murine monoclonal antibody 1D9 and a framework region derived from the heavy chain of human antibody 4B4′CL, wherein said antigen-binding fragment has binding specificity for CCR2.
A pharmaceutical composition comprising an antigen-binding fragment of a humanized immunoglobulin having binding specificity for CCR2 and a physiologically acceptable vehicle, wherein said immunoglobulin comprises a heavy chain and a light chain, wherein said light chain comprises a variable region comprising the amino acid sequence of SEQ ID NO:
- 107, and wherein said heavy chain comprises three complementarity determining regions derived from the heavy chain of murine monoclonal antibody 1D9 and a framework region derived from the heavy chain of human antibody 4B4′CL, and wherein said antigen-binding fragment has binding specificity for CCR2.
Dependencies are inferred from the claim text.